PAVmed Inc. shares fell 17.49% as the stock crossed below its 5-day SMA, reflecting a significant decline in market confidence.
The drop in PAVmed's stock comes despite its subsidiary, Lucid Diagnostics, securing a contract with the U.S. Department of Veterans Affairs for the EsoGuard test, which is expected to enhance access to cancer screening for over 9 million veterans. This contract is anticipated to strengthen Lucid's competitive position in the healthcare market, but the immediate market reaction has been negative, indicating a possible sector rotation or profit-taking by investors.
This decline in stock price may reflect broader market trends or investor sentiment shifting away from PAVmed, despite the positive news regarding the contract. The company's future performance will depend on how effectively it can leverage this contract to drive growth and investor confidence.
Wall Street analysts forecast PAVM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PAVM is 17.00 USD with a low forecast of 17.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast PAVM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PAVM is 17.00 USD with a low forecast of 17.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.120
Low
17.00
Averages
17.00
High
17.00
Current: 8.120
Low
17.00
Averages
17.00
High
17.00
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$19 → $20
2025-04-21
Reason
Ascendiant Capital
Edward Woo
Price Target
$19 → $20
AI Analysis
2025-04-21
Maintains
Strong Buy
Reason
About PAVM
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
